CheckMate 76K: Biomarker Analysis
Biomarker Analysis From CheckMate 76K Phase III Trial of Adjuvant Nivolumab vs Placebo in High-Risk Stage IIB/C Melanoma

Released: June 09, 2023

Activity

Progress
1
Course Completed